Low frequency of NS5A relevant resistance-associated substitutions to Elbasvir among hepatitis C virus genotype 1a in Spain: a cross-sectional study
C Palladino, M Sánchez-Carrillo, I Mate-Cano… - Scientific Reports, 2017 - nature.com
Relevant resistance-associated substitutions (RASs) to elbasvir, the new HCV NS5A
inhibitor, may limit its efficacy and lead to virological failure in HCV-GT1a-infected patients …
inhibitor, may limit its efficacy and lead to virological failure in HCV-GT1a-infected patients …
Prevalence of relevant NS5A resistance-associated substitutions to elbasvir in genotype 1a hepatitis C virus patients in Spain
C Palladino, B Esteban-Cartelle, I Mate-Cano… - … y microbiologia clinica …, 2018 - Elsevier
Resistance-associated substitutions (RASs) to the new HCV NS5A inhibitor elbasvir may
limit its efficacy and lead to virological failure in HCV-GT1a-infected patients. There are no …
limit its efficacy and lead to virological failure in HCV-GT1a-infected patients. There are no …
Epidemic history and baseline resistance to NS5A-specific direct acting drugs of hepatitis C virus in Spain
C Palladino, IJ Ezeonwumelu, I Mate-Cano… - Scientific reports, 2020 - nature.com
Hepatitis C virus (HCV) infection remains a global health problem. Previously, the
prevalence of NS5A resistance-associated substitutions (RASs) to elbasvir, a new direct …
prevalence of NS5A resistance-associated substitutions (RASs) to elbasvir, a new direct …
Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: a pooled analysis
T Asselah, H Reesink, J Gerstoft… - Liver …, 2018 - Wiley Online Library
Abstract Background & Aims The aim of this integrated analysis was to assess the efficacy of
the once‐daily combination of elbasvir 50 mg and grazoprevir 100 mg, with and without …
the once‐daily combination of elbasvir 50 mg and grazoprevir 100 mg, with and without …
Regulatory analysis of effects of hepatitis C virus NS5A polymorphisms on efficacy of elbasvir and grazoprevir
TE Komatsu, S Boyd, A Sherwat, LR Tracy, LK Naeger… - Gastroenterology, 2017 - Elsevier
Background & Aims Elbasvir (an NS5A inhibitor) and grazoprevir (an NS3/4A protease
inhibitor) are direct-acting antiviral agents recently approved in the United States for …
inhibitor) are direct-acting antiviral agents recently approved in the United States for …
[HTML][HTML] Effectiveness of elbasvir/grazoprevir plus ribavirin for hepatitis C virus genotype 1a infection and baseline NS5A resistance
DD Hill, JR Kramer, KR Chaffin, TC Mast… - Annals of …, 2023 - Elsevier
Abstract Introduction and Objectives In clinical trials, patients with hepatitis C virus (HCV)
genotype (GT) 1a infection and baseline resistance-associated substitutions (RASs) at …
genotype (GT) 1a infection and baseline resistance-associated substitutions (RASs) at …
Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir
R Liu, S Curry, P McMonagle, WW Yeh… - Antimicrobial agents …, 2015 - Am Soc Microbiol
Elbasvir is an investigational NS5A inhibitor with in vitro activity against multiple HCV
genotypes. Antiviral activity of elbasvir was measured in replicons derived from wild-type or …
genotypes. Antiviral activity of elbasvir was measured in replicons derived from wild-type or …
The cost‐effectiveness of testing for NS 5a resistance‐associated polymorphisms at baseline in genotype 1a‐infected (treatment‐naïve and treatment‐experienced) …
EH Elbasha, MN Robertson… - Alimentary …, 2017 - Wiley Online Library
Background The presence of baseline NS 5A resistance‐associated variants (RAV s)
impacted treatment response in HCV genotype 1a (GT 1a)‐infected patients treated with …
impacted treatment response in HCV genotype 1a (GT 1a)‐infected patients treated with …
The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection
S Zeuzem, L Serfaty, J Vierling, W Cheng… - Journal of …, 2018 - Springer
Background Genotype 1b (GT1b) is the most common subtype of the hepatitis C virus (HCV).
We present an integrated analysis of 1070 participants with HCV GT1b infection from 30 …
We present an integrated analysis of 1070 participants with HCV GT1b infection from 30 …
Comparison of naturally occurring resistance-associated substitutions between 2008 and 2016 in Chinese patients with chronic hepatitis C virus infection
W Huang, M Wang, Q Gong, D Yu, P Chen… - Microbial Drug …, 2019 - liebertpub.com
Aims: The presence of pre-existing hepatitis C virus (HCV) resistance-associated
substitutions (RASs) could attenuate viral susceptibility to direct-acting antiviral agents. The …
substitutions (RASs) could attenuate viral susceptibility to direct-acting antiviral agents. The …